Navigating the New Treatment Options in the Frontline Management of Advanced EGFR-Mutant NSCLC

EP: 1.An Expert Insights on Recent Advancements in LS-SCLC

EP: 2.The Key Updates in the Treatment of ES-SCLC

EP: 3.An Expert Perspectives on Tarlatamab in ES-SCLC

EP: 4.Looking Ahead With SCLC: ADCs and Other Novel Agents

EP: 5.The Shifting Paradigms With Perioperative Treatment Strategies in Early-Stage NSCLC

EP: 6.Personalizing Adjuvant Targeted Therapies in Early-Stage NSCLC

EP: 7.The New Targeted Approaches in Unresectable Early-Stage NSCL

Now Viewing

EP: 8.Navigating the New Treatment Options in the Frontline Management of Advanced EGFR-Mutant NSCLC

EP: 9.Expert Insights for the Treatment Sequencing in EGFR-Mutant Advanced NSCLC in the Second Line and Beyond

EP: 10.Latest Advances in Management of Advanced NSCLC with ALK or ROS1 Mutations

EP: 11.The Recent Updates in the Management Advanced NSCLC with HER2 or NRG1 Alterations

EP: 12.Tailoring Immunotherapy Strategies for the Advanced NSCLC

Video content above is prompted by the following:

• Briefly comment on the latest OS data from MARIPOSA andthe recentFDA approval (October 2024) of combination amivantamab and lazertinib as an advancement in the first-line treatment space.
• MARIPOSA Felip E, et al. ASCO 2024. Abs 8504; J&J press release, January 7, 2025
• Should this combination become the new standard of care for first-line treatment for certain patients?
• What is the remaining role for osimertinib with or without chemotherapy?
• How might the recent CRL for subcutaneous amivantamab impact clinical practice over the next year?